Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
SETHY
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer
- NCT07068542 ↗
- Recruiting
- Zhejiang Provincial People's Hospital
- Focused
We haven't built an HCP commentary report on SETHY (sacituzumab tirumotecan plus tislelizumab and sacituzumab tirumotecan in Advanced Thyroid Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SETHY so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 9 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Multi-Cohort, Phase II Study of Sacituzumab Tirumotecan With or Without Tislelizumab in Patients With Advanced Thyroid Cancer
- Phase
- Phase not applicable
- Status
- Recruiting
- Conditions
- Advanced Thyroid Carcinoma; Radioiodine-refractory Differentiated Thyroid Cancer; Poorly Differentiated Thyroid Carcinoma
- Interventions
- Sacituzumab Tirumotecan (SKB264) plus Tislelizumab; Sacituzumab Tirumotecan (SKB264)
- Arms
- cohort A · Experimental
- cohort B · Experimental
- cohort C · Experimental
- Enrollment
- 94 (estimated)
- Primary outcomes
- Overall Survival (OS) - ATC Cohort
- Progression-Free Survival (PFS) - PDTC and RAIR-DTC Cohorts
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Jul 1, 2025
- Primary completion
- Dec 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07068542 · updated Jun 1, 2026